Cargando…

Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing

Myelopathy is an increasingly recognized presentation of many antibody-mediated neuroinflammatory disorders. While specific features of certain autoimmune myelopathies such as aquaporin-4 antibody associated neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Passeri, Michlene, Matthews, Elizabeth, Kammeyer, Ryan, Piquet, Amanda L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366192/
https://www.ncbi.nlm.nih.gov/pubmed/35968301
http://dx.doi.org/10.3389/fneur.2022.972143
_version_ 1784765506731900928
author Passeri, Michlene
Matthews, Elizabeth
Kammeyer, Ryan
Piquet, Amanda L.
author_facet Passeri, Michlene
Matthews, Elizabeth
Kammeyer, Ryan
Piquet, Amanda L.
author_sort Passeri, Michlene
collection PubMed
description Myelopathy is an increasingly recognized presentation of many antibody-mediated neuroinflammatory disorders. While specific features of certain autoimmune myelopathies such as aquaporin-4 antibody associated neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein associated disorder (MOGAD) are well-characterized, other less commonly seen antibody-associated myelopathies are not as well-defined. These include but are not limited to, Hu/ANNA1, anti-glial fibrillary acidic protein (GFAP), anti-CV2/collapsin response mediator protein (CRMP5), and amphiphysin. Here, we review the mentioned more common antibody mediated myelopathies as well those that as less common, followed by a review of differentials that may mimic these disorders.
format Online
Article
Text
id pubmed-9366192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93661922022-08-12 Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing Passeri, Michlene Matthews, Elizabeth Kammeyer, Ryan Piquet, Amanda L. Front Neurol Neurology Myelopathy is an increasingly recognized presentation of many antibody-mediated neuroinflammatory disorders. While specific features of certain autoimmune myelopathies such as aquaporin-4 antibody associated neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein associated disorder (MOGAD) are well-characterized, other less commonly seen antibody-associated myelopathies are not as well-defined. These include but are not limited to, Hu/ANNA1, anti-glial fibrillary acidic protein (GFAP), anti-CV2/collapsin response mediator protein (CRMP5), and amphiphysin. Here, we review the mentioned more common antibody mediated myelopathies as well those that as less common, followed by a review of differentials that may mimic these disorders. Frontiers Media S.A. 2022-07-28 /pmc/articles/PMC9366192/ /pubmed/35968301 http://dx.doi.org/10.3389/fneur.2022.972143 Text en Copyright © 2022 Passeri, Matthews, Kammeyer and Piquet. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Passeri, Michlene
Matthews, Elizabeth
Kammeyer, Ryan
Piquet, Amanda L.
Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing
title Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing
title_full Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing
title_fullStr Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing
title_full_unstemmed Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing
title_short Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing
title_sort update in autoimmune and paraneoplastic myelopathies: newly described antigen targets and antibody testing
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366192/
https://www.ncbi.nlm.nih.gov/pubmed/35968301
http://dx.doi.org/10.3389/fneur.2022.972143
work_keys_str_mv AT passerimichlene updateinautoimmuneandparaneoplasticmyelopathiesnewlydescribedantigentargetsandantibodytesting
AT matthewselizabeth updateinautoimmuneandparaneoplasticmyelopathiesnewlydescribedantigentargetsandantibodytesting
AT kammeyerryan updateinautoimmuneandparaneoplasticmyelopathiesnewlydescribedantigentargetsandantibodytesting
AT piquetamandal updateinautoimmuneandparaneoplasticmyelopathiesnewlydescribedantigentargetsandantibodytesting